Mitomycin 40 — Mitomycin Injection IP 40 mg, 1 Single Use Vial

Mitomycin 40 is supplied as a sterile lyophilized powder for solution for injection/infusion:

• Presentation and Packaging: 1 glass vial made of amber-colored glass, sealed with a rubber stopper and aluminum flip-off seal with a green plastic cap. The vial contains a sterile, blue-violet to dark-violet lyophilized cake or powder. Each outer cardboard box contains 1 vial along with a detailed package insert.
• Active Ingredient:
  • Mitomycin C — 40 mg per single-use vial.
• Excipients: Mannitol (or sodium chloride as a lyoprotectant) to maintain iso-osmolarity and cake structure.

Pharmacodynamics: Mitomycin C is an antineoplastic antibiotic isolated from Streptomyces caespitosus. In tissues, it undergoes enzymatic reduction to generate an active alkylating species. It acts as a bi- and tri-functional alkylating agent. The activated drug selectively binds to guanine and cytosine residues, forming interstrand and intrastrand DNA cross-links. This inhibits DNA synthesis and, to a lesser extent, RNA and protein synthesis. Mitomycin C is most active in late G1 and early S phases of the cell cycle.

Pharmacokinetics: Following intravenous administration, Mitomycin C is rapidly distributed into body tissues but poorly crosses the blood-brain barrier (BBB). It is extensively metabolized, primarily in the liver, as well as in other tissues. Clearance occurs via enzymatic inactivation. The elimination half-life (T1/2) ranges from 25 to 50 minutes. Approximately 10–20% of the administered dose is excreted unchanged in the urine within 4 to 5 hours. Systemic absorption following intravesical instillation is minimal.

Mitomycin 40 is indicated for palliative or adjuvant single-agent or combination chemotherapy in the following malignancies:

• 🔹 Gastric and Pancreatic Adenocarcinoma: In combination with other antineoplastic agents (e.g., fluorouracil, doxorubicin) for advanced disease.
• 🔹 Breast Cancer: Locally advanced or metastatic breast carcinoma refractory to first-line regimens.
• 🔹 Non-Small Cell Lung Cancer (NSCLC): As part of multi-agent chemotherapy regimens.
• 🔹 Esophageal, Anal, and Cervical Cancers: Combined with radiotherapy and concurrent chemotherapy.
• 🔹 Superficial Bladder Cancer: Intravesical instillation for treatment and prophylaxis of recurrence following transurethral resection (TURBT).

Mitomycin 40 must be administered under the strict supervision of a qualified oncologist in a specialized setting:

• 👨‍⚕️ Intravenous Administration: The standard dose in monotherapy is 15–20 mg/m² body surface area IV slow bolus or short infusion every 6–8 weeks. In combination regimens, the dosage is reduced to 10–12 mg/m² every 6 weeks.
• 👨‍⚕️ Intravesical Instillation: For superficial bladder carcinoma, 20–40 mg dissolved in 20–40 mL of sterile water or 0.9% sodium chloride is instilled into the bladder via catheter and retained for 1–2 hours once weekly for 6–8 weeks.
• 👨‍⚕️ Reconstitution: Dissolve the lyophilized powder in sterile water for injection or 0.9% sodium chloride at a concentration not exceeding 1 mg/mL. The reconstituted solution must be clear and purple.
• 🥤 Hematologic Monitoring: Repeat cycles should only be administered after hematologic recovery (WBC > 4000/µL, platelets > 100,000/µL).

Mitomycin 40 is strictly contraindicated under the following conditions:

• ❌ Hypersensitivity to Mitomycin C or any excipients in the formulation.
• ❌ Severe bone marrow depression (severe leukopenia or thrombocytopenia).
• ❌ Coagulation disorders, bleeding diathesis, or active hemorrhage.
• ❌ Severe renal impairment (significantly elevated serum creatinine).
• ❌ Pregnancy and lactation (breastfeeding).

Clinically significant interactions with Mitomycin 40 include:

• ⚠️ Myelosuppressive Agents & Radiation: Concomitant use with other cytotoxic drugs or radiation therapy produces additive bone marrow suppression.
• ⚠️ Vinca Alkaloids: Severe acute bronchospasm and dyspnea have been reported when Mitomycin C is administered concurrently or sequentially with vinblastine/vinorelbine.
• ⚠️ Doxorubicin: Increased risk of cumulative cardiotoxicity.
• ⚠️ Live Vaccines: Vaccination with live viral vaccines during Mitomycin therapy is contraindicated due to the risk of severe systemic infection.

Mitomycin C possesses proven mutagenic, teratogenic, and embryo-fetal lethal properties:

• 🤰 Pregnancy: Mitomycin 40 is contraindicated during pregnancy. It can cause fetal harm and congenital malformations. Females of childbearing potential must use effective contraception during treatment and for at least 6 months thereafter.
• 🛡️ Male Contraception: Male patients receiving Mitomycin 40 must use reliable barrier contraception and refrain from fathering a child during treatment and for 3–6 months post-therapy.
• 🤱 Lactation: It is unknown whether Mitomycin C is excreted in human milk. Breastfeeding must be discontinued throughout therapy.

Possible adverse reactions associated with Mitomycin 40 treatment include:

• 🔴 Hematologic Toxicity: Cumulative leukopenia, thrombocytopenia (nadir typically occurs 4–8 weeks post-injection), and anemia.
• 🟡 Renal Toxicity: Elevated serum creatinine and BUN, Hemolytic Uremic Syndrome (HUS) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure.
• 🟠 Pulmonary Effects: Interstitial pneumonitis, pulmonary fibrosis, dyspnea, dry cough.
• 🟢 Gastrointestinal: Nausea, vomiting, stomatitis, anorexia, diarrhea, transient elevation of hepatic enzymes (ALT, AST).
• 🔵 Local Reactions: Severe soft tissue necrosis and phlebitis following extravasation. Dysuria, cystitis, and hematuria following intravesical administration.

Overdose management for Mitomycin 40:

• Symptoms: Severe bone marrow aplasia (agranulocytosis, severe bleeding due to thrombocytopenia), intractable nausea, vomiting, fever, and severe mucositis.
• Management: No specific antidote exists. Immediately discontinue the drug and initiate supportive care: blood component transfusions (packed RBCs, platelets), granulocyte colony-stimulating factors (G-CSF), and empiric broad-spectrum antibiotics for neutropenic fever. Hemodialysis is ineffective.

Storage and handling requirements for Mitomycin 40:

• Temperature: Store in the original carton at temperatures not exceeding 25 °C, protected from light and moisture.
• Reconstituted Solution: Use immediately after preparation. Reconstituted solutions protected from light may be stored at 2–8 °C for up to 24 hours.
• Safety: Store out of reach of children. Handle according to cytotoxic drug preparation guidelines.
• Shelf Life: 2 years (24 months) from manufacture date. Do not use past expiration date.

Visual identification guidelines for authentic Mitomycin 40 by Zydus Oncosciences:

• Carton Design: White outer box featuring a green cross emblem at the top with vertical green stripes. Front panel clearly prints: Mitomycin Injection IP 40mg, bold Mitomycin 40, Hindi text (मिटोमाइसिन ४०), a black dosage box stating 40 mg, and a green circular pattern icon.
• Branding: Displays the official Zydus Oncosciences corporate logo on both box and vial. Includes specific descriptors: For I.V. Infusion after dilution, SINGLE USE VIAL, and Lyophilized.
• Vial Packaging: Amber glass vial fitted with a green flip-off plastic cap sealed with an aluminum ring. The vial label mirrors the box design typography.
• Batch Details: Side panel of the carton and vial label feature laser-printed Batch No., Mfg. Date, Exp. Date, and Maximum Retail Price (M.R.P.).